A Novel Paradigm For Sacubitril/Valsartan: Beta-Endorphin Elevation As A Contributor To Exercise Tolerance Improvement In Rats With Preexisting Heart Failure Induced By Pressure-Overload

: Simultaneous angiotensin receptor (AT1) blockade and neprilysin inhibition with sacubitril/valsartan has been recently approved to treat patients with heart failure (HF). Therapeutic benefits of this therapy have been attributed to natriuretic peptide elevation and AT1 receptor blockade. However, this pharmacologic picture may not be complete. The aims of this study were to investigate the pharmacology of sacubitril/valsartan in comparison to monotherapies with sacubitril, and valsartan, and to examine their impact on peptides upregulated by neprilysin inhibition, such as beta-endorphin.
Source: Journal of Cardiac Failure - Category: Cardiology Authors: Source Type: research